Relapse is the commonest cause of treatment failure following bone marrow transplantation for malignant haematological disease. Treatment options are limited and often unsuccessful, with remissions, if achieved, being short-lived. Donor lymphocyte infusions have been used in the treatment of relapsing CML for several years, with good results being obtained. Use of this form of adoptive immunotherapy however, has been much less successful in patients with acute leukaemias, with acute lymphoblastic leukaemia appearing to be particularly resistant. We report the successful use of a donor lymphocyte infusion in a patient with isolated extramedullary relapse of acute lymphoblastic leukaemia post bone marrow transplantation. Keywords: adoptive immunotherapy; donor lymphocyte infusion; relapsed acute leukaemia; bone marrow transplantation Relapse following bone marrow transplantation for acute lymphoblastic leukaemia is the most frequent cause of treatment failure. Prognosis is poor, with limited treatment options available. Cell-mediated immunotherapy 1-4 has been used, appears to be effective, and is probably less toxic and safer than a second transplant.
Relapse following bone marrow transplantation for acute lymphoblastic leukaemia is the most frequent cause of treatment failure. Prognosis is poor, with limited treatment options available. Cell-mediated immunotherapy [1] [2] [3] [4] has been used, appears to be effective, and is probably less toxic and safer than a second transplant.
Slavin et al 5 were the first to use donor lymphocytes for relapse after allogeneic transplant. There have now been many reports of the use of donor lymphocyte infusions (DLI) to induce a graft-versus-leukaemia (GVL) effect and re-establish complete remission in patients with relapsed CML, with response rates of 60-90%. 2, 3, 6, 7 The major toxicity of DLI is graft-versus-host disease (GVHD) occurring in approximately 80%, and also myelosuppression which is seen in approximately 50%.
Experience with DLI in relapsed acute leukaemia is less and has generally been met with little success, with ALL appearing particularly resistant. [1] [2] [3] [4] 8 and two recent reports 7, 10 have also shown some response in this group of patients.
To our knowledge there have been no previous reports of the successful use of DLI in isolated extramedullary relapse of ALL. Here, we report achievement of a remission of 11 months with DLI in a child with isolated extramedullary relapse of acute lymphoblastic leukaemia 14 months post allogeneic BMT.
Case report
An 11-month-old boy presented with a short history of malaise, anorexia, irritability and bruising. Examination revealed lymphadenopathy, hepatosplenomegaly, petechiae and bruises. Investigations showed Hb 6 g/dl, WCC 267 × 10 9 /l and platelets 25 × 10 9 /l. Biochemistry was unremarkable. Peripheral blood and bone marrow morphology were consistent with L2 acute lymphoblastic leukaemia, and immunophenotyping with pre-B ALL. Cytogenetics were normal. CSF examination showed CNS infiltration.
He was commenced on treatment according to the MRC Infantile ALL protocol. Unfortunately, he failed to remit with this, but did respond to multi-agent chemotherapy attaining complete remission.
In view of his poor prognosis he received a first remission non-T cell-depleted HLA-identical BMT, with his mother as the donor (HLA typing was performed by DNA techniques, and by this method recipient and donor were phenotypically identical). Conditioning was with idarubicin, cyclophosphamide and total body irradiation. Engraftment occurred by day 14, being complicated by grade II skin GVHD which required treatment with oral prednisolone.
Post transplant he received monthly intrathecal methotrexate for 6 months. Seven months post transplant he experienced an isolated CNS relapse, presenting with a facial palsy. He received high-dose methotrexate and intrathecal chemotherapy, following which the CSF cleared and the facial palsy resolved.
Fourteen months post transplant he remained on immunosuppression for persistent skin GVHD with cyclosporin A and prednisolone. At this time he developed a further left-sided facial palsy, a parotid mass, lymphadenopathy and hepatomegaly. Biopsy of the parotid mass confirmed leukaemic recurrence. Bone marrow and CSF exam-ination were normal. Immunosuppression was withdrawn and within 1 month was accompanied by a small reduction in the size of the parotid mass and lymphadenopathy, and partial resolution of the facial palsy, with no exacerbation of his GVHD. After 2 months without immunosuppression there was still obvious disease present, and he then received an infusion of donor lymphocytes (2 × 10 8 /kg) obtained in a single apheresis without priming with growth factors. Infusion of donor lymphocytes was followed by grade III GVHD of the skin and liver, but did result in complete resolution of the parotid mass, lymphadenopathy and hepatomegaly by 6 weeks.
Currently, the patient has no evidence of leukaemic recurrence 11 months following DLI, although he remains on cyclosporin A, thalidomide and prednisolone for chronic skin GVHD.
Discussion
The most common cause of treatment failure following allogeneic BMT for haematological malignancies is relapse. Treatment options at this stage are limited and include further chemotherapy, irradiation, or a second bone marrow transplant. All these options are associated with high procedural morbidity and mortality, and remissions if obtained are often only short-lived. Cell-mediated immunotherapy is another option for patients relapsing post allogeneic BMT, appears to be effective and is probably safer than a second allograft.
Donor lymphocytes are thought to work by enhancing the GVL effect of BMT without necessarily inducing GVHD. Donor lymphocyte infusions have been used successfully in the treatment of CML relapsing post BMT for several years. 2, 3, 6, 7 Response rates of 60-90% are reported, with durable remissions. The major toxicities of this approach are GVHD and pancytopenia due to myelosuppression.
This form of adoptive immunotherapy has also been used in acute leukaemias relapsing post BMT but with much less success, and ALL appears to be particularly resistant. Of 135 patients studied by the EBMT only 29% of those with AML responded to DLI, and none of the patients with ALL. 2 Prentice et al 9 showed a response to donor lymphocytes in two patients with AML and two with ALL, but response was only seen in those pre-treated with chemotherapy, and both patients with ALL subsequently relapsed. In 1996, Porter et al 8 treated eight patients with relapsed acute leukaemia or myelodysplasia with DLI -only one achieved remission. Mehta et al 4 reported 11 patients treated with cell-mediated immunotherapy, with or without interferon. Two patients with AML/MDS were alive and in remission up to 20 months following DLI. Three patients with ALL were in the study and all showed a response to DLI, although two subsequently relapsed, and one died with GVHD. Collins et al 7 reported a response rate of 18.2% in patients with relapsed ALL, with a remission duration of 8 and 10 months. Atra et al 10 reported four cases of relapsed ALL in children post allogeneic BMT, three of whom showed a response to DLI, with remissions of between 7 and 11 months. None of the published reports, to our knowledge, describe responses in extramedullary relapse of ALL. We report here the successful use of DLI in attaining remission of 11 months to date in a child with an extramedullary relapse of ALL following allogeneic BMT. Immunosuppression had been withdrawn at the diagnosis of extramedullary relapse, and although a partial response was seen within 1 month, following a 2 month period without immunosuppression persistent disease was evident. Thus a DLI was given to enhance GVL activity and resulted in complete remission. The favourable response in this patient may have been due to the pattern of relapse already being influenced by an ongoing GVL effect, as there was no haematological relapse.
Cellular therapy, therefore, represents an alternative treatment option that can result in complete remission and increased disease-free survival when BMT has failed. The UKCCSG is currently looking at the role of a standardised dose and schedule of DLI in children relapsing with leukaemia post allogeneic BMT, and is also looking at the role of standard induction/consolidation therapy pre-DLI.
Although success with immunotherapy is limited in the case of acute leukaemias, and especially in ALL, this and other recently reported cases suggest that DLI may be effective in inducing remissions in ALL relapsing following allogeneic BMT.
